About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

45.33 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
From Scholar Rock, Inc.
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
Scholar Rock (SRRK) Q1 Loss Narrows In Line Awaits PDUFA Decision ↗
Via Chartmill
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Q4 Loss, Awaits Apitegromab Approval in 2026 ↗
Via Chartmill
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Q1 Earnings Call Highlights ↗
Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for... 
Via MarketBeat
Topics Earnings
News headline image
Scholar Rock (SRRK) Q1 2026 Earnings Transcript ↗
Scholar Rock (SRRK) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the BofA Securities 2026 Health Care Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock (SRRK) Q4 2025 Earnings Transcript ↗
Scholar Rock (SRRK) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies. 
Via The Motley Fool
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock to Present at Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026 ↗
The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Highlights 2026 Strategic Priorities
From Scholar Rock, Inc.
Via Business Wire
News headline image
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Scholar Rock, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.